Project Grant R61AR084188
Award Date
6/18/25
Completion Date
5/31/28
Dollars Obligated
$228K
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,543,226 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct a randomized controlled trial assessing the effects of sodium glucose transporter 2 (SGLT2) inhibitors on coronary flow reserve and epicardial adipose tissue in women living with HIV. The goal of this 5-year study is to...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under CFDA 93.846 Arthritis, Musculoskeletal and Skin Diseases Research provides $176,040 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct research focused on understanding the impact of glucocorticoid (GC) regimens on toxicities, clinical outcomes, and quality-of-life in vasculitis. The key research objectives are to: 1) evaluate the...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $1,205,522.00 to the University of Chicago to conduct a double-blind, randomized, sham-controlled pilot study on the use of genicular artery embolization (GAE) to reduce pain in patients with medically refractory mild to moderate knee osteoarthritis. The study aims to establish the...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $298,915 to Cyrus Biotechnology, Inc. to develop advanced uricase enzyme variants for improved treatment of gout. The key objectives are to engineer uricase proteins with enhanced stability, reduced immunogenicity, and extended half-life, which can address the limitations of current...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $317,304 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Duke University to develop a digital intervention to address non-adherence to hydroxychloroquine, a critical medication for adolescents with pediatric systemic lupus erythematosus (PSLE). The project aims to: 1) define an objective hydroxychloroquine concentration threshold to identify non-adherence, 2) develop...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under CFDA program 93.846 "Arthritis, Musculoskeletal and Skin Diseases Research", provides $177,650 to conduct an observational study on the use of anti-IL1 therapy to reduce flare activity and heterotopic ossification in patients with Fibrodysplasia Ossificans Progressiva (FOP), a rare disease causing progressive and irreversible loss of mobility. The key...
This Project Grant award of $405,350.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research aims to characterize lipid droplets in macrophage subsets and determine if manipulating lipid droplet content can shift macrophage function, with the goal of uncovering new therapeutic targets for systemic lupus erythematosus (SLE). The award recipient is The...
This Project Grant award of $570,878 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research to define the efficacy of pharmacological activation of the G-protein coupled receptor GPR68 in modulating tenocyte-myofibroblast dynamics during fibrotic tendon healing. The research aims to provide fundamental information related to regulation of the cell...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $297,940 to Case Western Reserve University from August 15, 2024 to July 31, 2026. The purpose is to develop patient- and parent-driven outcome measures for evaluating glandular inflammation and its flares, and their impact on quality of life and mental health for clinical trials related to...
This $358,000 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research at Brigham & Women's Hospital to elucidate social determinants of health and mental health needs in order to achieve equity in rheumatic disease care. The award will fund a 2-year study that leverages data from the All of Us research program to: Assess the effects of...